Atrion Corporation (ATRI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Atrion Corporation (ATRI) trades at $459.92 with AI Score 38/100 (Weak). Atrion Corporation develops, manufactures, and sells medical devices and components for fluid delivery, cardiovascular, and ophthalmology applications. Market cap: 809436204, Sector: Healthcare.
Last analyzed: Feb 8, 2026Atrion Corporation (ATRI) Healthcare & Pipeline Overview
Atrion Corporation delivers specialized medical devices across diverse healthcare applications, offering steady dividend yield and a strong market presence in fluid delivery, cardiovascular, and ophthalmology sectors, making it a stable investment within the medical instruments and supplies industry.
Investment Thesis
Atrion Corporation presents a notable research candidate due to its diversified product portfolio and established presence in niche medical device markets. With a current P/E ratio of 41.72 and a dividend yield of 1.91%, Atrion offers a blend of growth and income potential. The company’s consistent profitability, reflected in its 11.5% profit margin and 36.8% gross margin, underscores its operational efficiency. Growth catalysts include expanding applications of its fluid delivery systems and increasing demand for its cardiovascular and ophthalmology products. The company's focus on specialized medical devices provides a competitive edge, driving long-term value creation. Investors may want to evaluate Atrion for its stability, dividend payouts, and potential for growth in the medical device sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.81 billion, indicating a solid market presence.
- P/E ratio of 41.72, reflecting investor expectations of future earnings growth.
- Profit margin of 11.5%, showcasing the company's ability to generate profit from its revenue.
- Gross margin of 36.8%, demonstrating efficient cost management in production and sales.
- Dividend yield of 1.91%, providing a steady income stream for investors.
Competitors & Peers
Strengths
- Diversified product portfolio across multiple medical applications.
- Established relationships with key customers and distributors.
- Strong focus on innovation and product development.
- Consistent profitability and cash flow generation.
Weaknesses
- Relatively small size compared to larger medical device companies.
- Dependence on a limited number of key products.
- Potential for product liability claims.
- Vulnerability to changes in healthcare regulations.
Catalysts
- New product launches in the cardiovascular and ophthalmology segments expected in late 2026.
- Increasing demand for fluid delivery systems in oncology and anesthesia.
- Expansion of distribution network in emerging markets.
Risks
- Product liability claims related to medical devices.
- Changes in healthcare regulations affecting product approvals and reimbursement.
- Competition from larger medical device companies with greater resources.
- Economic downturns affecting healthcare spending.
Growth Opportunities
- Expansion of Fluid Delivery Systems: Atrion can capitalize on the growing demand for precise fluid management in medical procedures, particularly in oncology and anesthesia. The market for advanced fluid delivery systems is projected to reach $15 billion by 2028, driven by the increasing complexity of treatments and the need for improved patient outcomes. Atrion's innovative valve technology positions it well to capture a significant share of this expanding market.
- Increased Adoption of Cardiovascular Products: The rising prevalence of cardiovascular diseases globally drives the demand for Atrion's Myocardial Protection System and other cardiovascular devices. The global cardiovascular device market is expected to reach $60 billion by 2027. By focusing on technological advancements and strategic partnerships with hospitals and clinics, Atrion can increase the adoption of its cardiovascular products and expand its market reach.
- Growth in Ophthalmology Segment: Atrion's specialized medical devices for contact lens disinfection and nasolacrimal duct obstruction treatment address critical needs in the ophthalmology market. The global ophthalmology market is projected to reach $45 billion by 2026, driven by an aging population and increasing rates of eye disorders. Atrion can leverage this growth by expanding its product line and distribution network.
- Strategic Acquisitions and Partnerships: Atrion can pursue strategic acquisitions and partnerships to expand its product portfolio and enter new markets. By acquiring companies with complementary technologies or distribution channels, Atrion can accelerate its growth and enhance its competitive position. Potential acquisition targets include companies specializing in minimally invasive surgical instruments or advanced diagnostic devices.
- Geographic Expansion: Atrion has the opportunity to expand its presence in emerging markets, particularly in Asia-Pacific and Latin America, where healthcare spending is rapidly increasing. By establishing local distribution networks and tailoring its products to meet the specific needs of these markets, Atrion can tap into new sources of revenue and diversify its geographic footprint. The company can also explore partnerships with local manufacturers to reduce costs and improve market access.
Opportunities
- Expansion into new geographic markets.
- Strategic acquisitions of complementary businesses.
- Development of new products and applications.
- Increased adoption of telemedicine and remote patient monitoring.
Threats
- Intense competition from larger medical device companies.
- Pricing pressures from healthcare providers and payers.
- Technological obsolescence.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Specialized Product Portfolio: Atrion's focus on niche medical device markets creates a barrier to entry for competitors.
- Proprietary Technology: The company's patented valve technology and other innovations provide a competitive advantage.
- Established Customer Relationships: Long-standing relationships with physicians, hospitals, and other customers create customer loyalty.
- Regulatory Expertise: Navigating the complex regulatory environment for medical devices requires specialized knowledge and experience.
About ATRI
Founded in 1944 and headquartered in Allen, Texas, Atrion Corporation has evolved into a key player in the medical device industry. The company develops, manufactures, and sells a range of specialized medical devices and components used in fluid delivery, cardiovascular, and ophthalmology applications. Atrion's fluid delivery products include precision valves critical in anesthesia and oncology, enhancing infection control in healthcare settings. Their cardiovascular offerings feature the Myocardial Protection System, cardiac surgery vacuum relief valves, and silicone vessel loops, essential for heart bypass surgery. In ophthalmology, Atrion provides devices for contact lens disinfection and balloon catheters for treating nasolacrimal duct obstruction. Beyond these core areas, Atrion manufactures instrumentation for blood clotting measurement, safe needle containment products, and components for marine and aviation safety equipment. The company distributes its products globally through a direct sales force, independent representatives, and distributors, serving physicians, hospitals, clinics, and other medical equipment manufacturers. Atrion's commitment to innovation and quality has solidified its position as a trusted provider of specialized medical solutions.
What They Do
- Develops and manufactures fluid delivery products for medical applications.
- Produces cardiovascular devices used in heart surgery and related procedures.
- Offers specialized medical devices for ophthalmology, including contact lens disinfection.
- Manufactures instrumentation for measuring blood clotting time.
- Creates products for safe needle and scalpel blade containment.
- Supplies inflation systems and valves for marine and aviation safety products.
- Provides components for inflatable survival products and structures.
- Offers pressure relief valves for protecting sensitive electronics during transport.
Business Model
- Develops and manufactures specialized medical devices and components.
- Sells products directly to physicians, hospitals, and clinics.
- Utilizes independent sales representatives and distributors to reach a wider market.
- Generates revenue through product sales and ongoing service contracts.
Industry Context
Atrion Corporation operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand due to an aging global population and advancements in medical technology. The industry is highly competitive, with key players focusing on specialized products and solutions. Atrion's focus on niche markets within fluid delivery, cardiovascular, and ophthalmology applications allows it to maintain a competitive edge. Competitors include AORT (Aortica Corporation), ASLN (Assure Holdings Corp), CDMO (Avid Bioservices Inc), CMRX (Chimerix Inc), and CSII (Cardiovascular Systems Inc), each vying for market share in specialized segments. The industry is expected to see steady growth, driven by technological advancements and increasing healthcare expenditure.
Key Customers
- Physicians specializing in cardiology, ophthalmology, and anesthesia.
- Hospitals and clinics providing surgical and medical treatments.
- Other medical equipment manufacturers incorporating Atrion's components into their products.
- Customers in marine and aviation industries requiring safety equipment.
ATRI Financials
ATRI Price Today & Live Chart
Atrion Corporation (ATRI) stock price: $459.92 (+0.26, +0.06%)
ATRI Latest News
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Sep 26, 2022
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Sep 22, 2022
-
Stocks That Hit 52-Week Lows On Monday
· Mar 16, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
ATRI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATRI.
Price Targets
Wall Street price target analysis for ATRI.
ATRI MoonshotScore
What does this score mean?
The MoonshotScore rates ATRI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Common Questions About ATRI (Healthcare)
What does Atrion Corporation do?
Atrion Corporation is a medical device company that develops, manufactures, and sells specialized products for fluid delivery, cardiovascular, and ophthalmology applications. The company's products include valves, cardiovascular devices, ophthalmic instruments, and other medical components. Atrion serves physicians, hospitals, and other medical equipment manufacturers through a direct sales force, independent representatives, and distributors. The company's focus on niche markets and proprietary technology allows it to maintain a competitive edge in the medical device industry.
Is ATRI stock worth researching?
ATRI stock presents a mixed investment profile. Its P/E ratio of 41.72 suggests it may be overvalued compared to industry peers, but its dividend yield of 1.91% offers some income potential. The company's consistent profitability, with a profit margin of 11.5% and gross margin of 36.8%, indicates financial stability. Growth opportunities in fluid delivery, cardiovascular, and ophthalmology segments could drive future stock appreciation. Investors should weigh the valuation concerns against the company's growth prospects and dividend payouts before making a decision.
What are the main risks for ATRI?
Atrion faces several risks, including potential product liability claims related to its medical devices, changes in healthcare regulations affecting product approvals and reimbursement, and intense competition from larger medical device companies with greater resources. Economic downturns could also affect healthcare spending and demand for Atrion's products. These risks could negatively impact the company's financial performance and stock price. Investors should carefully consider these risks before investing in ATRI.
What are the key factors to evaluate for ATRI?
Atrion Corporation (ATRI) currently holds an AI score of 38/100, indicating low score. Key strength: Diversified product portfolio across multiple medical applications. Primary risk to monitor: Product liability claims related to medical devices. This is not financial advice.
How frequently does ATRI data refresh on this page?
ATRI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ATRI's recent stock price performance?
Recent price movement in Atrion Corporation (ATRI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio across multiple medical applications. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ATRI overvalued or undervalued right now?
Determining whether Atrion Corporation (ATRI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ATRI?
Before investing in Atrion Corporation (ATRI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Future growth opportunities are subject to market conditions and competitive pressures.